Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Indo US Bio-Tech's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 38.06.
Indo US Bio-Tech's Days Inventory for the
three
months ended in Jun. 2026 was 345.201.
Indo US Bio-Tech's Days Payable for the
three
months ended in Jun. 2026 was 1.536.
Therefore, Indo US Bio-Tech's Cash Conversion Cycle (CCC) for the
three
months ended in Jun. 2026 was 381.73.
Indo US Bio-Tech (BOM:541304) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Indo US Bio-Tech Cash Conversion Cycle Related Terms
Indo US Bio-Tech Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Indo US Bio-Tech's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:541304 vs CTVA, CF, MOS: Cash Conversion Cycle Comparison
For the Agricultural Inputs subindustry, Indo US Bio-Tech's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indo US Bio-Tech Cash Conversion Cycle vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Indo US Bio-Tech's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Indo US Bio-Tech's Cash Conversion Cycle falls into.
Indo US Bio-Tech Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Indo US Bio-Tech's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indo US Bio-Tech (BOM:541304) has a Cash Conversion Cycle of 381.73 as of Jun. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Indo US Bio-Tech and its competitors.
Is Indo US Bio-Tech's Cash Conversion Cycle too high?
Indo US Bio-Tech's current Cash Conversion Cycle is 381.73. The Agriculture industry median Cash Conversion Cycle is 102.87. Indo US Bio-Tech's value of 381.73 is 271.1% above this industry median. Overall, Indo US Bio-Tech has a GF Score™ of 77/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indo US Bio-Tech's Cash Conversion Cycle compare to CTVA and CF?
Indo US Bio-Tech's Cash Conversion Cycle of 381.73 can be compared against companies in the Agriculture industry. The industry median Cash Conversion Cycle is 102.87. Indo US Bio-Tech's value of 381.73 is 271.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for an Agriculture company?
The median Cash Conversion Cycle among Agriculture companies is 102.87, based on 252 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indo US Bio-Tech's current Cash Conversion Cycle of 381.73 is 271.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Indo US Bio-Tech and its competitors. For the Agriculture industry, the median Cash Conversion Cycle is 102.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indo US Bio-Tech's current Cash Conversion Cycle is 381.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo US Bio-Tech stock overvalued right now?
Based on GuruFocus' analysis, Indo US Bio-Tech (BOM:541304) is currently considered Possible Value Trap. The stock's GF Value™ is ₹298.00, compared to a current price of ₹77.20 — trading 74.1% below its estimated fair value. The current Cash Conversion Cycle is 381.73 and 271.1% above the Agriculture industry median of 102.87. Indo US Bio-Tech's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Indo US Bio-Tech (BOM:541304), the current Cash Conversion Cycle is 381.73 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indo US Bio-Tech (BOM:541304) Overvalued in 2026?
Based on GuruFocus' analysis, Indo US Bio-Tech stock appears to be undervalued.
The current stock price of ₹77.20 is trading 74.1% below its estimated GF Value™ of ₹298.00.
GuruFocus considers Indo US Bio-Tech to be Possible Value Trap.
Key valuation signals for BOM:541304:
Cash Conversion Cycle: 381.73
GF Value™: ₹298.00 vs. price of ₹77.20 (74.1% below fair value)
Industry Position: 271.1% above the Agriculture median
No single metric tells the full story. See the BOM:541304 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indo US Bio-Tech Ltd is an Indian agriculture seed company engaged in crop research, breeding, seed production, processing, packing, and marketing. It develops and sells hybrid and open-pollinated seed varieties, with a portfolio spanning vegetable seeds such as tomato, okra, brinjal, onion, cucumber, and bottle gourd, along with oilseeds including groundnut and mustard, pulses, cereals such as wheat and bajra, and spice seeds. The company serves farmers and agricultural distributors across India through its seed brands and dealer network. Its revenue model centers on the sale of packaged seeds to the agricultural market, supported by in-house research and development, contract seed multiplication, and processing facilities. By offering improved varieties with traits such as higher yield and disease tolerance, Indo US Bio-Tech positions itself in the domestic hybrid seed segment of India's input agriculture industry.
77GF Score
Get the complete analysis for BOM:541304
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:541304 has been successfully added to your 
